External validity of a trial comprised of elderly patients with hormone receptor-positive breast cancer

Journal of the National Cancer Institute

Volumn 106, Issue 4, 2014, Pages

  Van De Water, Willemien ^a   Kiderlen, Mandy ^a   Bastiaannet, Esther ^a   Siesling, Sabine ^b,c   Westendorp, Rudi G J ^a   Van De Velde, Cornelis J H ^a   Nortier, Johan W R ^a   Seynaeve, Caroline ^d   De Craen, Anton J M ^a   Liefers, Gerrit Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Cancer Registry and Research   (Netherlands)

^c UNIVERSITY OF TWENTE   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; EXEMESTANE; PROGESTERONE RECEPTOR; TAMOXIFEN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; BREAST TUMOR; CHEMISTRY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; NETHERLANDS; RANDOMIZED CONTROLLED TRIAL; REGISTER; REPRODUCIBILITY; RISK; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; NETHERLANDS; ODDS RATIO; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; REPRODUCIBILITY OF RESULTS; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84898877199     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju051     Document Type: Article

References (30)

1. Cancer of the Breast. SEER Stat Fact Sheets. http://seer.cancer.gov/stat- facts/html/breast.html#incidence-mortality. Accessed September 6, 2012.
2. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61(6):409-418.
3. Mell LK, Jeong JH, Nichols MA, Polite BN, Weichselbaum RR, Chmura SJ. Predictors of competing mortality in early breast cancer. Cancer. 2010;116(23):5365-5373.
4. Aapro M, Bernard-Marty C, Brain EG, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol. 2011;22(2):257-267.
5. Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther. 2007;32(2):169-175.
6. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21(7):1383-1389.
7. Zulman DM, Sussman JB, Chen X, Cigolle CT, Blaum CS, Hayward RA. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med. 2011;26(7):783-790.
8. Hutchins L F, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061-2067.
9. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemes-tane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377(9762):321-331.
10. van Nes JG, Seynaeve C, Jones S, et al. Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. Br J Surg. 2010;97(5):671-679.
11. de Glas NA, Kiderlen M, Bastiaannet E, et al. Postoperative complications and survival of elderly breast cancer patients: a FOCUS study analysis. Breast Cancer Res Treat. 2013;138(2):561-569.
12. World Health Organization. The International Statistical Classification of Diseases and Related Health Problems ICD-10; 2010. http://apps.who.int/ classifications/icd10/browse/2010/en. Accessed April 1, 2013.
13. Tesser P, Van Praag C, Van Dugteren F, Herweijer L, Van der Wouden H. Rapportage minderheden 1995. Rijswijk/Den Haag, the Netherlands: Sociaal en Cultureel Planbureau/VUGA; 2013.
14. Conference communication: age categorization proposed at oral session, accessible for members only. Paper discussed at International Society of Geriatric Oncology Annual Meeting; October 15-17, 2009; Berlin, Germany.
15. van de Water W, Markopoulos C, van de Velde CJ, et al. Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA. 2012;307(6):590-597.
16. Andersen PK, Geskus RB, de WT, Putter H. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol. 2012;41(3):861-870.
17. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239-241.
18. Lu TH, Shih T P, Lee MC, Chou MC, Lin CK. Diversity in death certification: a case vignette approach. J Clin Epidemiol. 2001;54(11):1086- 1093.
19. Harteloh P, de Bruin K, Kardaun J. The reliability of cause-of-death coding in the Netherlands. Eur J Epidemiol. 2010;25(8):531-538.
20. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
21. Fine J P, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;(94):496-509.
22. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389-2430.
23. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet. 2005;365(9453):82-93.
24. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297(11):1233-1240.
25. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23(13):3112-3124.
26. Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol. 2003;21(12):2268-2275.
27. Kornblith AB, Kemeny M, Peterson BL, et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer. 2002;95(5):989-996.
28. Townsley CA, Chan KK, Pond GR, Marquez C, Siu LL, Straus SE. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer. 2006;6:34.
29. Hamaker ME, Seynaeve C, Nortier JW, et al. Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study. Breast. 2013;22(4):556-559.
30. Vandenbroucke J P. When are observational studies as credible as randomised trials? Lancet. 2004;363(9422):1728-1731.